pylori associated to Irritable Bowel Syndrome (IBS) selleck chemical Barrios F. A., Barrios A., Álvarez A., Mendez E., Digestive Endoscopy Unit, Las Torres Clinic, Quetzaltenango, Guatemala. AIMS. Objective: To determine the role of H. Pylori in the pathogenesis of Irritable Bowel Syndrome (IBS). We previously demonstrated that the presence of biliary acids in the stomach (Duodeno-gastric Reflux Disease, DGRD) changes the gastric pH, favoring the growth of H. Pylori, as this bacterium is sensitive to pH values bellow 4.5. We investigated that the presence of H. Pylori in the colonic

mucosa in patients with IBD. Methods: Colonoscopy, Biopsy and Rapid Urease Test (CLO-Test). All patients have been diagnosed and treated for IBS, without any improvement. Results: Universe: 47 patients were studied. MALE: 21 (45%), FEMALE: 26 (55%). H. Pylori Positives 25 (53%). H. Pylori Negatives 22 (47%). One patient in this study, previously presented

Colonic Carcinoma. Conclusion: All patients showed improvement, including the patient with Colonic Carcinoma, which in the beginning presented 99% of stricture and after one month of treatment, the stricture decreased to 50%. Accordingly, we consider that the presence of H. Pylori in the colonic mucosa is just another important co-factor in the pathogenesis of IBS and probably in the development of Colonic Carcinoma. Subjects were administered H. Pylori treatment. Key Word(s): 1. IBD; 2. H. pylori; 3. Colonic Cancer; 4. Clotest; Presenting Author: YAN PAN Additional Authors: QIN OUYANG Corresponding Author: find more QIN OUYANG Affiliations: Department of Gastroenterology, West China Hospital Objective: Ulcerative colitis (UC) is thought to result from inappropriate and ongoing activation of the mucosal immune system. In China, UC mostly affect

left sided colon and topical therapy play a vital role in UC treatment. The trial was carried out to investigate the efficacy and safety of Baweixileisan (BWXLS) enema, a compound of traditional Chinese herbal medicine and to explore the therapeutical MCE公司 mechanisms. Methods: A prospective randomized controlled trial was carried out. Patients with active left-sided mild to moderate UC from the outpatient clinic of West China Hospital from June, 2009 to October, 2010 were allocated alternatively into treatment group with BWXLS enama 1 g/60 ml and the control group with hydrocortisone enema 50 mg/60 ml for 4 weeks. The clinical, endoscopic and histologic manifestations were evaluated according to the protocols in the end of trial. The expression of TLR4, NF-κB and Occludin were investigated immunohistochemically before and after the treatment. Results: 103 patients were included. The clinical remission rate and response rate in the treatment group were 78.2% and 89.1% respectively and 58.3% and 72.9% in the control (p < 0.05). Endoscopically, mucosal healing rate was 50.9% in the treatment group and 31.3% in the control (p < 0.05).